Paul Robeson and Jackie Robinson never met in person. During certain periods in their lives, both men were held up by white America as examples of proof that in the US anyone can make it if they apply ...

Welcome to Going Private, I’m Sinead Cruise and this is Bloomberg’s twice-weekly newsletter about private markets and the forces moving capital away from the public eye. Today, we look at threats to ...

A top AI researcher says most people are using AI in ways that weaken thinking. Vivienne Ming's experiment found that only a small minority use AI to challenge and improve ideas. She says users should ...

I make short, to-the-point online math tutorials. I struggled with math growing up and have been able to use those experiences to help students improve in math through practical applications and tips.

Are you using AI to think — or letting it think for you? Vivienne Ming, chief scientist at the Possibility Institute, a metascience research group, and founder of Socos Labs, an AI and education firm, ...

The fight demonstrates the data center industry’s enduring political power, even as much of the public sours on the energy-hungry facilities. Virginia Democrats are divided over a tax break for data ...

Dreaming of a garden that plants itself? Imagine low-maintenance perennials that spread gracefully, fill empty spaces, and bring a buzzing, fluttering wildness to your backyard all with minimal effort ...

Suffering from hair envy? You can now use the same hair products that Manon, Yoonchae, Sophia, Megan, Lara, and Daniela use to get their glossy locks. Manon's go-to products from Matrix are a ...

EXCLUSIVE: Adam Hendricks and Greg Gilreath of Divide/Conquer, the genre production company behind the M3GAN films, Heart Eyes and more, are set to exec produce Play House, a new micro-budget horror ...

This is read by an automated voice. Please report any issues or inconsistencies here. Oscar nominations are officially out, meaning for the next couple of months social media feeds will be saturated ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...